Compare BridgeBio Pharma Inc (BBIO) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.35 (market cap $141.17B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 8.7× BridgeBio Pharma Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.25% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | BBVA | |
|---|---|---|
Market Cap | $16.27B | $141.17B |
Sector | Health | Financials |
52-Week High | $90.17 | $26.14 |
52-Week Low | $44.81 | $14.73 |
Enterprise Value | $17.82B | — |
Dividend Yield | — | 4.25% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
